Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Quantitative interpretation of Sedia LAg Assay test results after HIV diagnosis

View ORCID ProfileJoseph Sempa, View ORCID ProfileEduard Grebe, View ORCID ProfileAlex Welte
doi: https://doi.org/10.1101/2021.09.13.21263495
Joseph Sempa
1Department of Biostatistics, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa
3South African Department of Science and Technology - National Research Foundation Centre of Excellence in Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joseph Sempa
  • For correspondence: sempajb@ufs.ac.za
Eduard Grebe
3South African Department of Science and Technology - National Research Foundation Centre of Excellence in Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa
2Vitalant Research Institute, San Francisco, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eduard Grebe
Alex Welte
3South African Department of Science and Technology - National Research Foundation Centre of Excellence in Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alex Welte
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Testing for ‘recent HIV infection’ is common in surveillance, where only population-level estimates (of incidence) are reported. Typically, ‘recent infection’ is a category, obtained by applying a threshold on an underlying continuous biomarker from some laboratory assay(s). Somehow interpreting the biomarker values obtained for individual subjects, for example interpreting them as estimates of the date of infection, has obvious potential applications in the context of studies of early infection, and has also for some years attracted significant interest as an extra component of post-test counselling and treatment initiation. The applicable analyses have typically run aground on the complexity of the full biomarker growth model, which is in principle a non-linear mixed-effects model of unknown structure, the fitting of which seems infeasible from realistically obtainable data.

Methods It is known that to estimate Mean Duration of Recent Infection (MDRI) at a given value of the recent/non-recent -infection discrimination threshold, one may compress the full biomarker growth model into a relation capturing the probability of a recent test result as a function of time since infection. Noting that the time-derivative (gradient) of this curve (for a value of threshold – h) is identical to the formal likelihood relevant to Bayesian inference of the infection date, for a subject yielding an assay result * h * on the date of their first positive HIV test. This observation bypasses the need for fitting a complex detailed biomarker growth model. Using publicly available data from the CEPHIA collaboration, we calculated curves for a range of thresholds for the Sedia Lag assay and performed Bayesian inference of infection data, given a uniform prior implied by a last negative and first positive test.

Results We demonstrate the generation of posteriors for infection date, for patients with various delays between their last negative and first positive HIV test, and a range of LAg assay results (ODn) hypothetically obtained on the date of the first positive result.

Conclusion Depending on the last-negative / first-positive interval, there is a range of ODn values that yields posteriors significantly different from the uniform prior one would be left with based merely on interval censoring. Hence, a LAg ODn obtained on the date of, or soon after, diagnosis contains potentially significant information about infection dating. It seems worth analysing other assays with meaningful dynamic range, especially tests already routinely used in primary HIV diagnosis (for example chemiluminescent assays and reader/cartridge lateral flow tests which admit objective variable line intensity readings) which have a sufficient dynamic range that corresponds to a clinically meaningful range of times-since-infection that are worth distinguishing from each other.

Competing Interest Statement

The authors do not have any competing interests.

Funding Statement

This study was funded by the DST-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa and the University of the Free State.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The data used in the publication was published as part of Sempa et al. 2019.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • This article has been revised to include a link to the R Shiny app that we have developed to generate posterior curves.

Data Availability

All the data used in this manuscript was already published in a previous article PMID: 31348809.

https://doi.org/10.1371/journal.pone.0220345.s008

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted November 12, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Quantitative interpretation of Sedia LAg Assay test results after HIV diagnosis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Quantitative interpretation of Sedia LAg Assay test results after HIV diagnosis
Joseph Sempa, Eduard Grebe, Alex Welte
medRxiv 2021.09.13.21263495; doi: https://doi.org/10.1101/2021.09.13.21263495
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Quantitative interpretation of Sedia LAg Assay test results after HIV diagnosis
Joseph Sempa, Eduard Grebe, Alex Welte
medRxiv 2021.09.13.21263495; doi: https://doi.org/10.1101/2021.09.13.21263495

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1099)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9781)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2317)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (605)
  • Hematology (238)
  • HIV/AIDS (506)
  • Infectious Diseases (except HIV/AIDS) (11655)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (239)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2146)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (365)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (312)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2187)
  • Public and Global Health (4672)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)